OXYT
Oxytocin
A cyclic nonapeptide closed by a disulfide bridge between the cysteines at positions 1 and 6, leaving a three-residue tail. It binds the oxytocin receptor. It differs from vasopressin at only two of nine positions, which is why the two peptides show measurable cross-reactivity at each other's receptors.
Oxytocin has 648 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 110,136 planned or enrolled participants across the 628 studies that published a figure. An FDA-approved product contains Oxytocin — OXYTOCIN (ANDA200219). 9,063 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Oxytocin; the registry search is fuzzy, so every match is re-checked. None of this says whether Oxytocin works or is safe.
FDA status
Approved
Human studies
648
Furthest phase
Phase 4
Papers, 10 yr
9,063
Readership
25,916
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
An approved product exists
648
Registered human studies
Phase 4
Furthest phase reached
110,136
Planned or enrolled participants, across 628 studies that published a figure
Approved
FDA-approved product — OXYTOCIN
919 loose registry matches were checked and 648 confirmed — 271 named something else and were discarded. We count a study only when Oxytocin is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Oxytocin is, and what it has been studied for
Oxytocin is tracked here. Its FDA substance identifier is 1JQS135EYN.
Across 648 registered trials, it has been studied in Postpartum Hemorrhage, Healthy, Schizophrenia and Oxytocin. A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by University of Electronic Science and Technology of China and Samuel Lunenfeld Research Institute, Mount Sinai Hospital among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Oxytocin reached Phase 4 across 648 registered trials.
An FDA-approved product contains Oxytocin. Approval covers a specific product for a specific use — it is not a verdict on the molecule.
Is anyone studying Oxytocin?
Papers published each year that name Oxytocin in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 1023 | 42 | Yes |
| 2018 | 1065 | 35 | Yes |
| 2019 | 1058 | 37 | Yes |
| 2020 | 1097 | 32 | Yes |
| 2021 | 1142 | 28 | Yes |
| 2022 | 1085 | 31 | Yes |
| 2023 | 1003 | 35 | Yes |
| 2024 | 1026 | 34 | Yes |
| 2025 | 1137 | 26 | Yes |
| 2026 | 773 | 14 | No |
9,063 papers and 314 registered trials between 2017 and 2026. A paper counts when “Oxytocin” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Oxytocin
9,063 indexed papers name Oxytocin in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- The physiology and pharmacology of oxytocin in labor and in the peripartum period
- Is Oxytocin "Nature's Medicine"?
- Maternal plasma levels of oxytocin during breastfeeding-A systematic review
- Neural circuitry for maternal oxytocin release induced by infant cries
- Oxytocin signaling regulates maternally directed behavior during early life
- Oxytocin enables maternal behaviour by balancing cortical inhibition
- Oxytocin in neurodevelopmental disorders: Autism spectrum disorder and Prader-Willi syndrome
- Oxytocin: A developmental journey
Collected 2026-08-02from PubMed, phrase-matched on “Oxytocin” in title and abstract. Run the same search.
About Oxytocin
A cyclic nonapeptide closed by a disulfide bridge between the cysteines at positions 1 and 6, leaving a three-residue tail. It binds the oxytocin receptor. It differs from vasopressin at only two of nine positions, which is why the two peptides show measurable cross-reactivity at each other's receptors.
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.